AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-14. (Cancelled)

15. (Previously presented) A compounds with a general formula (I)



in which



m is the number 0 or 1;

Z and Z' are an integer ranging from 0 to 2 when they are different or are an integer ranging from 1 to 2 when they are the same;

Y and Y', which can be the same or different, are $(CH_2)_{n1}$; $(CH_2)_{n2}$-CH[$NR^{VII}(CH_2)_{n4}$-NHR^{I}]-$(CH_2)_{n3}$; CH_2-CH[CH_2-CH_2]$_2$- or $(CH_2)_{n2}$-N[$(CH_2)_{n4}$-NHR^{IV}]-$(CH_2)_{n3}$;

Y" is selected from the group consisting of H; cycloalkyl C3-C7; $(CH_2)_{n5}$-$N[CH_2$-$CH_2]_2N$-$(CH_2)n_6NHR^V$; $(CH2)n_7$ $CH[CH_2$- $CH_2]_2NR^v$;

X is O, or is a simple bond;

n-n7, which can be the same or different, are an integer ranging from 0 to 5;

R^I, R^{II}, R^{III}, R^{IV}, and R^V, which can be the same or different, are a protective group for the nitrogen to which they are bound; CO_2R^{VI} ; CO_2CH_2Ar; CO_2(9-fluorenylmethyl); $(CH_2)_{n5}$-$NHCO_2R^{VI}$; CH_2Ar; COAr; $(CH_2)_{n5}$-$NHCO_2CH_2Ar$; $(CH2)_{n5}$-$NHCO_2$-(9-fluorenylmethyl).

R^{VI} is a straight or branched (C_1-C_6) alkyl;

R^{VII} is H or R^I-R^V;

Ar is a C_6-C_{12} aromatic residue, phenyl, optionally substituted with one or more groups selected from: halogen, hydroxy, C_1-C_5 alkyl, C_1-C_5 alkoxy, phenyl, cyano, nitro, $-NR^{VIII}R^{IX}$, where R^{VIII} and R^{IX}, which can be the same or different, are hydrogen, straight or branched (C_1-C_5) alkyl, or Ar is a heterocyclic group, said heterocyclic group containing at least one heteroatom selected from a nitrogen atom, optionally substituted with a (C_1-C_5) alkyl group, and/or oxygen and/or sulphur; said heterocycle can be substituted with one or more groups selected from halogen, hydroxy, C_1-C_5 alkyl, C_1-C_5 alkoxy, phenyl, cyano, nitro,

$-NR^{VIII}R^{IX}$, where R^{VIII} and R^{IX}, which can be the same or different, are hydrogen, straight or branched (C_1-C_5) alkyl, the N1-oxides, racemic mixtures, their individua enantiomers, their individuai diastereoisomers, the E and Z forms, their mixtures, and pharmaceutically acceptable salts.

16. (Previously presented) A compound according to claim 15, in which the protective groups are bulky groups of a lipophilic nature.

17. (Previously presented) A compound according to claim 15, in which the protective groups are selected from the group consisting of: CO_2R^{VI}; CO_2CH_2Ar; CO_2-(9-fluorenylmethyl); $(CH_2)_{n5}$-NH CO_2R^{VI}; $(CH2)_{n5}$-$NHCO_2CH_2Ar$; $(CH2)_{n5}$-$NHCO_2$-(9-fluorenylmethyl), in which R^{VI} is as defined above.

18. (Previously presented) A compound according to claim 17, in which the protective groups are selected from the group consisting of tert-butoxycarbonyl; benzyloxycarbonyl; 9-fluorenylmethyloxycarbonyl.

19. (Previously presented) A compound according to claim 15, in which m is 0.

20. (Previously presented) A compound according to claim 19, selected from the group consisting of:

tert-butylester of 20S-(4-{[3-(7-camptothecinylidene-amino)-propyl]-tert-butoxycarbonyl-amino}-butyl)-(3-tert-butoxycarbonylaminopropyl)-carbamic acid;

tert-butylester of 20S-(4-{[3-(7-camptothecinylidene-amino)-propyl]-tertbutoxycarbonyl-amino}-butyl)-carbamic acid; and

benzyl ester of 20S-(4-{[3-(7-camptothecinylidene-amino)-propyl]-benzyloxycarbonyl-amino}-butyl)-carbamic acid.

21. (Previously presented) A compound according to claim 15, in which m is 1.

22. (Previously presented) A compound according to claim 21, selected from the group consisting of:

tert-butylester of 20RS-(4-{[3-(7-homocamptothecinylidene-amino)-propyl]-tertbutoxycarbonyl-amino}-butyl)-(3-tert-butoxycarbonylaminopropyl)-carbamic acid;

tert-butylester of 20RS-(4-{[3-(7-homocampto-thecinylidene-amino)-propyl]-tertbutoxycarbonyl-

amino}-butyl)-carbamic acid; and

benzyl ester of 20S-(4-{[3-(7-homocamptothecinylidene-amino)-propyl]-benzyloxycarbonyl-amino}-butyl)-carbamic acid.

23. (Previously presented) A pharmaceutical composition containing at least one compound according to claim 15 as the active ingredient in admixture with at least one pharmaceutically acceptable vehicle and/or excipient.

24. (Previously presented) A method of inhibiting topoisomerase comprising administering to a subject in the need of the same an effective amount of a compound of claims 15.

25. (Cancelled).

26. (Previously presented) A method of combating parasites comprising administering to a subject in the need of the same an effective amount of a compound of claims 15.

27. (Previously presented) A method of treating a virus disease comprising administering to a subject in the need of the same an effective amount of a compound of claims 15.

28. (Currently amended) The method according to claim [[25]]15 wherein said cancer is lung cancer, non-microcytoma lung cancer, colorectal cancer, gastric cancer, prostate cancer or glioma.

29. (Currently amended) The method according to claim [[25]]15 wherein said cancer is non-microcytoma lung cancer or gastric cancer.